Denali Therapeutics 2026: Revenue $17.78M, Net income $70.13M, EPS $0.37— 10-Q Summary

What happened

Denali Therapeutics reported 2026 revenue of $17.78 million, compared with no revenue in the prior-year period, and net income of $70.13 million versus a $126.9 million loss. Diluted earnings per share were $0.37, compared with a loss of $0.74 per share.

Confirmed

Global impact / market context

The shift to reported revenue and profit may improve investor views of Denali’s finances, but the article says AVLAYAH revenue is not expected to cover expenses soon. That means ongoing research and operating costs may still require cash beyond product sales.

Analyst inference

The results accompany early commercial sales and a pipeline with several clinical programs advancing, while one Parkinson’s program ended after missing trial endpoints. Investors must weigh AVLAYAH’s revenue contribution against costs and the uncertainty of turning clinical progress into future sales.

Analyst inference

What to watch

1. Track whether AVLAYAH sales continue after U.S. distribution began in April, and whether the reported $21.4 million in product revenue through September grows enough to contribute more toward expenses. Analyst inference
2. Watch for updates on zafinofusp’s Phase 3 start-up and the stated 2027 accelerated-approval filing timeline; neither a filing nor approval is reported as completed. Confirmed
3. Assess whether ongoing development of DNL593 after Takeda returned its rights can proceed, while noting that the article gives no future trial timing or funding details. Analyst inference

Evidence

• Original source link unavailable